Articles Posted in Mass Torts

This page is for victims considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates on these claims, explain the litigation process, and predict Depo Provera settlement amounts.

A new scientific study has provided stunning evidence that using Depo-Provera can cause brain tumors. Women who used Depo-Provera and subsequently developed a meningioma brain tumor can file a Depo-Provera lawsuit seeking financial compensation. This new evidence is leading to a wave of Depo-Provera lawsuits nationwide.

Our attorneys are taking these cases in all 50 states. If you think you have a Depo Provera lawsuit, call us today at 800-553-8082 or contact us online.

This page is about social media addiction lawsuits and who is eligible to bring a claim. Our lawyers also provide the latest news on social media class action lawsuits (including the ongoing trial in California).

The problem that led to social media lawsuits is that millions of people, too many of whom are children, are addicted to social media platforms such as Facebook, Instagram, Snapchat, and others. For these vulnerable users, social media addiction can be very harmful and lead to things like eating disorders, depression, and, in some cases, suicide.

Now, these companies are facing a wave of new social media lawsuits alleging that they knowingly designed the algorithms of their platforms to lure young people into harmful addictions.

A spinal cord stimulator is an implantable medical device used to manage chronic pain, most often involving the back or spine. These systems are marketed as a way to reduce pain by interrupting nerve signals before they reach the brain. But for a growing number of patients, the device fails to help. It introduces new and sometimes permanent problems, including electrical shocks, burning pain, infections, lead migration, hardware failure, and repeat surgeries to reposition or remove equipment that was supposed to improve quality of life.

This page explains spinal cord stimulator lawsuits and why they are being filed nationwide. It focuses on what patients are alleging, how these devices have failed in real-world use, and why many of these cases go beyond ordinary medical malpractice claims. The most serious lawsuits do not center on a single surgical mistake. They examine how modern spinal cord stimulators were designed, tested, and approved, and whether patients were ever adequately warned about the risks that now recur repeatedly in medical records and FDA reports.

Many people arrive here with a practical question in mind: what do spinal cord stimulator settlement amounts look like, and how does compensation get calculated when a device causes lasting harm? That question cannot be answered in isolation. Settlement amounts and payouts are driven by the full medical timeline, including the cost of repeat surgeries, explantation, permanent loss of function, and the downstream consequences when a pain-management device leaves someone worse off than before it was implanted.

Our lawyers are investigating gambling addiction lawsuits involving DraftKings, FanDuel, BetMGM, Caesars, ESPN Bet, Bet365, Fanatics Sportsbook, Hard Rock Bet, and other online betting platforms. The core allegation is that these companies had the data to see compulsive gambling behavior and, instead of slowing users down, kept pushing them with bonus bets, deposit matches, push notifications, VIP hosts, profit boosts, same game parlays, microbets, and personalized offers.

If you or your child suffered serious harm from online sports betting addiction, the first question is not whether gambling was legal. The first question is whether the platform used design, data, and marketing to keep a vulnerable user betting when a responsible operator should have stepped in.

If you or someone you love has suffered severe financial and emotional harm because of addiction to online gambling or sports betting, contact our lawyers at 800-553-8082 or get a free, no-obligation online consultation.

Our lawyers are handling AFFF firefighting foam lawsuits around the country.

This page provides the most recent news and updates on the AFFF firefighting foam class action lawsuit and our prediction of the settlement amounts that plaintiffs with AFFF cancer lawsuits can expect to receive. You will not get more updated news on the AFFF litigation anywhere else.

Our AFFF firefighting foam lawyers believe the defendants will settle most of these lawsuits this year (2026) before a single trial.  Why? They will follow the same pattern as the water contamination lawsuits they settled for billions of dollars.  In those cases, we saw the defendants’ apparent preference for settlement over the uncertainties of a trial.  This makes sense; the AFFF lawsuits are strong cases.

Our lawyers are handling Taxotere eye injury lawsuits throughout the United States for women with permanently watery eyes from docetaxel.

Taxotere (docetaxel) is a widely used breast cancer chemotherapy drug. New evidence has emerged showing that Taxotere may be causing some users to suffer permanent vision loss or damage.

This has led to a wave of product liability Taxotere lawsuits by women who claim that Taxotere damaged their eyesight. The manufacturer of Taxotere, Sanofi, allegedly knew about the risk of vision damage but chose not to warn doctors or patients about this risk.

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas. On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, and other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different.

The lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma, often called CTCL, can mimic eczema and that Dupixent may mask, accelerate, or delay diagnosis of an underlying lymphoma. Plaintiffs argue that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and to stop and investigate if symptoms worsened or changed during treatment.

Contact Information